


Piramal Critical Care Announces the U.S. Launch of Edaravone Injection

Bethlehem, PA – September 18, 2024: Piramal Critical Care (PCC), a division of Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), today, announced the launch of Edaravone Injection in the U.S. Edaravone Injection will be offered in 30 mg/100 mL strength. With this launch, PCC continues to expand their generic injectables portfolio. [Full prescribing information available here.](#)



Peter DeYoung, Chief Executive Officer of Piramal Global Pharma commented: “We are excited to launch Edaravone Injection, which joins our growing US portfolio of injectable products at Piramal Critical Care. It further complements our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.”

The launch of Edaravone Injection (30 mg/100 mL) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2024, PCC launched a new concentration of Zinc Sulfate for Injection, USP, which followed launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP in 2023 to further enhance their wide portfolio of critical care products.

About Piramal Critical Care:

Piramal Critical Care (PCC) is a global leader in anesthesia, pain management, and intrathecal therapy. Piramal Critical Care maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. Their product portfolio includes inhaled anesthetics, intrathecal treatments for spasticity and pain management, plasma volume expanders, and a variety of other injectables and generics. Piramal Critical Care has strong manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India with global regulatory accreditations and adherence to strict GMP regulations. In addition, Piramal Critical Care partners with leading pharmaceutical development and manufacturing organizations around the world.

For more information visit <http://www.PiramalCriticalCare.us> | [LinkedIn](#)

About Piramal Pharma Ltd.:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL's associate companies, AbbVie Therapeutics India Private Limited, a joint venture between AbbVie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the

Piramal Critical Care, Inc.

3950 Schelden Circle, Bethlehem, Pennsylvania 18017-8936

Telephone: 610-974-9760 Fax: 610-861-4746

piramalcriticalcare.com



Carlyle Group. For more information visit: <http://www.piramal.com/pharma> | [LinkedIn](#) | [Twitter](#)

For Queries:

Gagan Borana

Investor Relations & Enterprise Risk Management

gagan.borana@piramal.com

*Includes one facility through minority investment in Yapan Bio.

Piramal Critical Care, Inc.

3950 Schelden Circle, Bethlehem, Pennsylvania 18017-8936

Telephone: 610-974-9760 Fax: 610-861-4746

piramalcriticalcare.com